Quick Summary
- The FDA has granted 510(k) authorization to Tempus AI for ECG-PH, an artificial intelligence platform that identifies pulmonary hypertension indicators through standard 12-lead electrocardiogram analysis.
- ECG-PH represents Tempus’ third FDA-authorized cardiovascular artificial intelligence solution, complementing existing clearances for atrial fibrillation detection and low ejection fraction identification.
- Approximately 1% of the general population lives with pulmonary hypertension, with prevalence climbing to 10% among individuals over age 65.
- The technology serves as a supplementary clinical tool rather than a primary diagnostic instrument and requires integration with additional patient information.
- Usage parameters restrict the software to patients 40 years or older presenting cardiovascular symptoms without existing pulmonary hypertension diagnoses.
Tempus AI (TEM) has obtained FDA 510(k) authorization for its ECG-PH platform, an artificial intelligence-driven software solution that identifies pulmonary hypertension indicators through analysis of conventional 12-lead electrocardiogram data.
This authorization represents the company’s third FDA-cleared cardiovascular artificial intelligence diagnostic product. Tempus has previously secured regulatory approval for diagnostic tools focused on detecting atrial fibrillation and identifying low ejection fraction conditions.
Pulmonary hypertension develops when blood vessels within the lungs become rigid and constricted, creating excessive strain on the heart’s right chambers. The condition impacts approximately 1% of people globally and affects as many as 10% of the population aged 65 and above.
Even with its prevalence, pulmonary hypertension often goes undetected. Initial manifestations including exhaustion and breathing difficulty can be easily dismissed, while definitive diagnosis traditionally requires right heart catheterization—an invasive medical procedure.
Tempus ECG-PH addresses this diagnostic gap. The platform examines stationary, non-ambulatory 12-lead ECG data and identifies markers of increased mean pulmonary artery pressure, a key indicator of pulmonary hypertension.
Intended Patient Population
The software targets patients 40 years of age or older experiencing cardiovascular manifestations including breathing difficulty, exhaustion, chest discomfort, or swelling, who have not received a prior pulmonary hypertension diagnosis.
The system delivers a binary assessment—indicating either the presence or absence of risk markers. Healthcare providers must consider this output within the context of comprehensive patient evaluation.
Tempus emphasizes that ECG-PH functions as a supplementary clinical tool rather than a definitive diagnostic solution. Interpretation requires consideration of the original electrocardiogram, patient symptoms, diagnostic history, and additional clinical findings.
The platform is not designed for continuous monitoring applications and cannot process electrocardiograms displaying paced cardiac rhythms.
Expanding Cardiovascular AI Capabilities
Dr. Brandon Fornwalt, MD, PhD, who serves as Senior Vice President of Cardiology at Tempus, explained that this authorization aligns with the company’s strategic initiative to leverage artificial intelligence for earlier cardiovascular risk identification.
“Pulmonary hypertension has historically been underdiagnosed because early symptoms are non-specific and gold-standard diagnostics are invasive,” Fornwalt said.
He emphasized that the organization aims to assist medical professionals in recognizing patients “across the spectrum of cardiovascular disease.”
Tempus maintains one of the world’s most extensive multimodal healthcare data repositories and deploys artificial intelligence solutions across numerous clinical specialties beyond cardiology.
The ECG-PH authorization enhances a cardiovascular artificial intelligence suite that now addresses three separate conditions, each utilizing the standard 12-lead electrocardiogram as primary data input.
The FDA 510(k) regulatory framework applies to medical devices demonstrating substantial equivalence to previously authorized commercial devices, representing a standard approval route for software-based diagnostic technologies.
Tempus ECG-PH has received clearance for deployment within healthcare institutions using clinical diagnostic electrocardiogram recordings.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
